Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision		 Previous revision
dupilumab [2025/03/07 01:49] – Scott Larsondupilumab [2025/06/14 04:11] (current) – [Resources] Scott Larson
Line 1: Line 1:
 ====== Dupilumab ====== ====== Dupilumab ======
-a.k.a. Dupixent+a.k.a. Dupixent used to treat atopic atopic disease (dermatitis, asthma, chronic rhinosinusitis) 
  
 ====Ocular Complications==== ====Ocular Complications====
-  * Reported in those with atopic dermatitis (more often than with placebo)+  * Reported in clinical trials (more often than with placebo)
     * conjunctivitis     * conjunctivitis
     * keratitis     * keratitis
Line 15: Line 15:
  
 ==== Resources ==== ==== Resources ====
-{{::dupilumab-associated_ocular_manifestations-review_of_clinical_presentations_and_management_2022.pdf | Wu D et al. Dupilumab-associated ocular manifestations: A review of clinical presentations and managment. Surv Ophthalmol. 2022;67(5):1419-1422}}+[[https://1drv.ms/b/c/31d83ae8e55e0542/EW0RbSa-6SpHloMpdwjZYugBzs9tLRJYcJbgGCtykQccbw?e=tBGRwv | Wu D et al. Dupilumab-associated ocular manifestations: A review of clinical presentations and managment. Surv Ophthalmol. 2022;67(5):1419-1422]]
  
  
-{{tag>drug}}+{{tag>drugs}}